This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Pirenoxine is a medication indicated to treat cataracts.
- Generic Name
- Pirenoxine
- DrugBank Accession Number
- DB15945
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Pirenoxine (DB15945)
- Weight
- Average: 308.249
Monoisotopic: 308.043321366 - Chemical Formula
- C16H8N2O5
- Synonyms
- Pirenoxina
- Pirenoxine
- Pirenoxinum
- External IDs
- 213-872-4
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Cataracts •••••••••••• ••• • ••••••••• ••• •••••••• ••••••• •••••••• • •••••• ••••••• ••• •••••••• Treatment of Cataracts •••••••••••• •••••••• ••••••••• ••••• •••••••• ••••••• •••••••• • •••••• ••••••• ••• •••••••• Treatment of Cataracts •••••••••••• ••••••• ••••••• ••• ••••••••• •••••••••• • ••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Pirenoxine sodium 95JU7URF64 51410-30-1 HDQXPMXHXZNPKE-UHFFFAOYSA-M
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 27L0EP6IZK
- CAS number
- 1043-21-6
- InChI Key
- OKPNYGAWTYOBFZ-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H8N2O5/c19-9-5-8(16(21)22)18-14-10(20)6-12-15(13(9)14)17-7-3-1-2-4-11(7)23-12/h1-6H,(H,18,19)(H,21,22)
- IUPAC Name
- 4-hydroxy-12-oxo-12H-10-oxa-1,5-diazatetraphene-2-carboxylic acid
- SMILES
- OC(=O)C1=NC2=C(C(O)=C1)C1=NC3=CC=CC=C3OC1=CC2=O
References
- General References
- AIFA: Clarvisan PVA (Pirenoxine) Ophthalmic Solution [Link]
- External Links
- ChemSpider
- 4680
- 228080
- ChEBI
- 32013
- ChEMBL
- CHEMBL1372341
- ZINC
- ZINC000011616009
- Wikipedia
- Pirenoxine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution / drops Ophthalmic 0.376 mg Liquid Ophthalmic 0.05 mg/1ml Solution Ophthalmic 0.05 mg/ml Solution / drops Ophthalmic Powder, for solution Ophthalmic 0.005 % Solution / drops; tablet, for solution Ophthalmic 0.75 mg/1tablet - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.129 mg/mL ALOGPS logP 1.82 ALOGPS logP -0.12 Chemaxon logS -3.4 ALOGPS pKa (Strongest Acidic) 0.79 Chemaxon pKa (Strongest Basic) 6.02 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 109.08 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 81.43 m3·mol-1 Chemaxon Polarizability 29.5 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0019000000-937eefe5a57e5f666bdc Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-0090000000-067e633ffe873d1cbe83 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0019000000-79e627bb73f348750bd5 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-0090000000-da142a5fb4b3c8b3dcf6 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0090000000-c16b5e67c7be447d294e Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-03di-0092000000-6fa607475905fb609bfa Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 164.48184 predictedDeepCCS 1.0 (2019) [M+H]+ 166.84004 predictedDeepCCS 1.0 (2019) [M+Na]+ 173.44258 predictedDeepCCS 1.0 (2019)
Drug created at November 26, 2020 14:21 / Updated at May 07, 2021 21:09